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• Field trials results
• Conclusions and 
Perspectives
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Rabies: Old Disease 
New Challenges
Rabies is an important causative agent of disease 
resulting in an acute infection of the nervous system 
and death 
Rabies remains endemic throughout the world. 
• 55,000 deaths per year (WHO)
• Major Public health issue 
Global reservoir in domestic and wildlife animals 
including dogs, foxes, raccoons, skunks, coyotes, 
mongooses and bats
Oral Rabies Vaccine (ORV) is a publicly acceptable 
methodology that may be applied on a broad 




Between 1958 and 1990 there was an 
average of 1,500 confirmed cases of 
wildlife rabies per year.
Since 1989 OMNR has used oral 
vaccines as a tool to control wildlife 
rabies.  Program has been very 
successful.
In 2009 there were only 16 confirmed 
cases in terrestrial mammals.  50% in 
skunks.
Available oral rabies vaccines were 
ineffective in skunk.
Control of rabies in wildlife remains 
an important challenge.
A human adenovirus rabies 
glycoprotein recombinant vaccine 
(AdRG1.3) was developed for oral 
vaccination: Yarosh et al. 1996, Vaccine
AdRG1.3 rabies vaccine is produced 
by cell culture process using HEK 293 
cell. 
Large quantity of vaccine is required for field trials 











Well characterized up- & 
downstream bioprocesses
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Reduction of immunogenicity & toxicity
Improved transgene capacity
Lower production yield & increased complexity of production 
system
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HEK293 a platform for 





Adenovirus vaccines 500L Kamen et al., J. gene 
medicine, 2004 P21
Gutless AdV Muscular Dystrophy 3L Dormond et al., 
Biotechnol.Bioeng, 2009
Reovirus Oncolytic 100L Transfiguration et al. 
J.PBA, 2008 P21
Influenza H1N1 Vaccine 3L Le Ru et al. Vaccine, 2010
P20
AAV Interferon 3L Durocher et al., VirMet, 
2007. P9
Retrovirus Marker 3L, perfusion Ghani et al., 
Biotechnol.Bioeng, 2006
Lentivirus Marker 3L, perfusion Ansorge et al. JGM 2009.
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Improvement of 
Production yield and 
Process Robustness
1. Selection of  a basal 
medium
2. Medium development 
3. Increase in cell density
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• Improved production process resulting in 
– 50% saving in material expenses and 
– 25% reduction in labor costs
– More robust process
• Improved AdRG1.3 viral yield by a 
factor of three   through optimization of 
cell culture media
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Successful Scale-up of 
AdV-based ORV 
vaccine
~ 12000L of AdRG1.3 (ONRAB) at 
1011 VP/mL produced for field trials
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ORV Baiting
Vaccine-filled baits are distributed throughout the 
area by airplanes. 
Key component in the baits is adenovirus type 5 




Aerial baiting of 
rabies vaccine
Rabies vaccine bait developed by Ontario 
Ministry of Natural Resources Baits will be distributed by plane. 
Aerial baiting is done using a bait machine. Aerial baiting is part of Ontario’s 
rabies control program. 
Sources: Ontario Ministry of Natural Resources
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Vaccine efficacy in 
Raccoons
Rosatte et al. (2009) Journal of Wildlife Diseases, 2009, 45:363-374 
22
Vaccine efficacy in 
Raccoons (2010)







• Successful process optimization and scale-up for 
manufacturing of an adenovirus-base ORV
• Production of  >> 5 millions baits for field trials
• Succesful technology transfer for manufacturing 
of adenovirus-based ORV 
• Highly efficient ORV based on 2006/07 field trials 
• This ORV-related program has potentially broad 
appplications in developing countries where most 
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